Cervomed Inc. · NASDAQ:CRVO
Cervomed — Diffusion Pharmaceuticals — Investor Presentation (September 2020)
29 slides from Cervomed's investor presentation, Sep 15, 2020
Slide 1: Diffusion Pharmaceuticals: New Treatments for Hypoxia
Nasdaq: DFFN Diffusion Pharmaceuticals New Treatments for Hypoxia September 2020
Slide 2: Forward-looking statement
Forward-looking statement ‘Thece stateme ‘This presentation contains ‘forward-looking statements’ within the meaning of U.S. securities la include, but may not be limited to, our operating and ‘growth strategy, including our ongoing and planned preclinical and clinical trials, product development pl
Slide 3: An Exciting New Approach for Hypoxia
An Exciting New Approach New Treatments. for Hypoxia fusion Pharmaceuticals
Slide 4: Diffusion Pharmaceuticals is a clinical-stage biopharma company
Diffusion Pharmaceuticals is a clinical-stage biopharma company dedicated to improving clinical outcomes for patients afflicted with life- threatening conditions where cellular oxygen deprivation (known as “hypoxia") is a key factor, including stroke, heart attack, the treatment of cancer and respir
Slide 5: Pipeline Highlights
Pipeline Highlights TARGETING AGENTS mTORC-Driven DFN-529 Malignancies sc Acute stroke __ sD GBM (130+ Radiat |, Chemotherapy) GENERATION aa ———— | biffeson Pharmaceuticals
Slide 6: Oxygen is Essential for Life
Oxygen is Essential for Life The body's tissues require a constant flow of oxygen Oxygen enters the body through the lungs where it is loaded into red blood cells, delivered by the circulatory system and off-loaded to the body's organs and tissues. Movement of oxygen from blood to tissue occurs via
Slide 7: Hypoxia is a Key Driver of Unmet Medical Needs
Hypoxia Hypoxia is a Key Driver of Unmet Medical Needs. Hypoxia is a lower than normal concentration of oxygen in a tissue Sustained hypoxia can lead to tissue death and even organ failure, as seen in many life-threatening conditions, including stroke, heart attack, cancer and respiratory diseases,
Slide 8: Potential strategies to improve tissue oxygenation
Potential strategies to improve tissue oxygenation Enhancing the diffusivity of O; is a novel approach to treating hypoxia bifeson Pharmaceuticals Itis not currently possibleto change intercellular distancesin vivo Effective, butmechanical ventilation increases adverse events < Facilitate movernento
Slide 9: Mechanism of Action
Mechanism of Action Blood plasma is 90% water. Water molecules are constantly moving in a loosely organized matrix, bound together by a chemical attractive force known as hydrogen bonding. TSC works by causing water molecules to create more hydrogen bonds among themselves, forming a more organized m
Slide 10: TSC Reduces Hypoxia in Rat Brain Cancer Model
TSC Reduces Hypoxia in Rat Brain Cancer Model Re-oxygenation to enhance radiosensitization of the tumor f" Without TS 45 minutes after TSC biffeson Pharmaceuticals i)
Slide 11: TSC as a Therapy in COVID-19
ae TSC asa . os ; Therapy in (A — COVID-19
Slide 12: Many patients with COVID-19 experience acute lung impairment
Many patients with COVID-19 infections experience acute lung impairment, which can lead to tissue hypoxia and organ failure
Slide 13: TSC as a Potential Therapy in COVID-19
TSC as a Potential Therapy in COVID-19 ‘* Many patients with COVID-I9 infections experience acute lung impairment and suffer from hypoxia * TSC has demonstrated the ability to reverse hypoxic conditions in animal models of lung injury as well as other conditions related to hypoxia TSC has a novel me
Slide 14: TSC COVID-19 Clinical Strategy
TSC COVID-19 Clinical Strategy N Primary Endpoint: Safety and Tolerability ‘Secondary Endpoints: PK/PD (blood 02), multiple clinical endpoints Topline data: Anticipated 492020 biffeson Pharmaceuticals Randomized, placebo-controlled clinical trial to support registration International trial to be con
Slide 15: Other Indications
Other Indications
Slide 16: Broad Potential Value of TSC as a Treatment for Hypoxia-related Conditions
Broad Potential Va as a Treatment for S¢ lige) Robust preclinical efficacy in multiple animal models (rat and rabbit) Enrollment in current Phase 2 trial paused due to COVID-19 Opportunity to evaluate the stroke trial in the context of the COVID-19 study data ue of TSC Hypoxia-related Conditions Str
Slide 17: TSC as a Potential Stroke Treatment
TSC as a Potential Stroke Treatment
Slide 18: TSC as a Potential Stroke Treatment
TSC as a Potential Stroke Treatment Stroke is characterized by restricted blood flow to the brain, caused by a clot (ischemic) or a bleed (hemorrhage) The resulting hypoxia drives the rapid destruction of neurons, leading to impairment and death. Time to treatment is critical. Only approved drug for
Slide 19: TSC Shows Preclinical Efficacy In Ischemic Stroke
TSC Shows Preclinical Efficacy In Ischemic Stroke Mg of clots needed for 501 of rabbits to show some deficit biffeson Pharmaceuticals Ischemic Stroke: Rabbits 4 ss 3 ss @ Control @ TsCalone 2 @ tPA alone 1 ME T5C and tPA 0 Thour 3 hour Time of drug dosing, hours after clotinfection Statistical signi
Slide 20: TSC Shows Preclinical Efficacy In Hemorrhagic Stroke
TSC Shows Preclinical Efficacy In Hemorrhagic Perihematomal Neuronal Cell Death in Rat Hemorrhagic Stroke Model 12000 10000 Fluorojade 8000 Positive Cells 6000 4000 2000 0 Control TSC alone 55 = statistical significance biffeson Pharmaceuticals Stroke a
Slide 21: TSC as a Potential Cancer Treatment
TSC as a Potential Cancer Treatment
Slide 22: TSC as a Potential Cancer Treatment
TSC as a Potential Cancer Treatment Hypoxia is a common feature in solid malignancies and contributes to chemotherapy and radiation resistance as well as metastasis © Hypoxia occurs in glioblastoma multiforme (‘GBM’) due to poor oxygen diffusion related to increased cell proliferatior/tumor growth L
Slide 23: Glioblastoma Phase 2 Clinical Trial design
Glioblastoma Phase 2 Clinical Trials 59 newly diagnosed GBM patients enrolled at 18 cancer centers Open-label, historical control study TSC dosed 3x/week for 6 weeks concurrent with standard radiation and chemotherapy (temozolomide) biffeson Pharmaceuticals Patients stratified post-hoc Surgery for t
Slide 24: Phase 2 Glioblastoma Clinical Trial Results (Inoperable Patients)
Phase 2 Glioblastoma Clinical Trial RESULES (inoperabte Patients) Overall Survival at | And 2 Years (Hx Control vs TSC) Median Survival in Months (Hx Control vs TSC) Months 94 snd 2 Year Neuro-Oncology 26)5°S602, Ane 200 Prolonged surihal fer astente wien nen epnecee mogerdle glodlsztoms.... Parc 1
Slide 25: Financial Highlights
Financial Highlights June Common Shares Potentially Dilutive Shares: Restricted shares Warrants Stock options Total Dilutive Shares Total Fully Diluted Common Shares biffeson Pharmaceuticals 63,998,298 98,100 1,427,829 9,117,209 10,643,138 74,641,346 Cash, cash equivalents and short-term investments
Slide 26: Leadership team
Leadership team Robert Cobuzzi, r, PhD Chief Executive Officer, Director 2yearsof cross-functional leaders ipin pharmaceutical and biotechnology industries, including Endo, dolor, Centocor, ActraMerck. Thomas E. Byrne, JD (GC and Patents Thomas Byene Ee ites’ intelletual property strategy since the
Slide 27: Board of Directors
Board of Directors David G. Kalergis, JD/MBA Chairman and Co-founder the co-founder of Diffusion Pharmaceuticals David kalergi Alan Levin, MBA Chairman ofthe Auait Committee Pharma Financial Executive, Former EVP & CFO of Endo Health Solutions, Former &.CFO of Przer MarkT. Giles, JD Lead independent
Slide 28: Highlights
Highlights An exciting new approach to treat hypoxia ¢ Trans sodium crocetinate (TSC) targets hypoxic conditions, a core feature of many diseases with high unmet medical need, including COVID-19 Pending outcome of the safety/proof-of-concepttrial in COVID-19 patients, an international randomized ada
Slide 29: Thank you
Diffusion Pharmaceuticals — Investor Presentation (September 2020) on 6ix